

WEST**End of Result Set**☐

Generate Collection

L6: Entry 2 of 2

File: DWPI

May 11, 2000

DERWENT-ACC-NO: 1997-526402

DERWENT-WEEK: 200031

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Ligand inhibitor of insulin-like growth factor binding - used to increase level of free growth factor and treat growth factor-responsive conditions

DID:

WO 9739032 A1

ABTX:

A novel ligand inhibitor (A) that inhibits binding of insulin-like growth factor (IGF) to IGF binding protein (IGFBP) is used for: (a) increasing the level of free, biologically active IGF in a patient; or (b) treating an IGF-responsive condition. Also new are: (1) a method for screening for small molecule (A); and (2) ligand inhibitors (A') that inhibit binding of some protein (I) to IGFBP used in a method for increasing the level of free, active (I).

WEST[Generate Collection](#)**Search Results - Record(s) 1 through 2 of 2 returned.**☐ 1. Document ID: WO 9739032 A1

L5: Entry 1 of 2

File: EPAB

Oct 23, 1997

PUB-NO: WO009739032A1

DOCUMENT-IDENTIFIER: WO 9739032 A1

TITLE: TITLE DATA NOT AVAILABLE

PUBN-DATE: October 23, 1997

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 2. Document ID: AU 200010144 A, WO 9739032 A1 , AU 9726762 A, EP 854884 A1, JP 11508608 W, MX 9710291 A1

L5: Entry 2 of 2

File: DWPI

May 11, 2000

DERWENT-ACC-NO: 1997-526402

DERWENT-WEEK: 200031

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Ligand inhibitor of insulin-like growth factor binding - used to increase level of free growth factor and treat growth factor-responsive conditions

INVENTOR: BEHAN, D; GAUR, A ; LING, N ; LIU, X

PRIORITY-DATA: 1996US-0633934 (April 17, 1996), 2000AU-0010144 (January 7, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 200010144 A	May 11, 2000	N/A	000	G01N033/74
<u>WO 9739032 A1</u>	October 23, 1997	E	035	C07K014/65
AU 9726762 A	November 7, 1997	N/A	000	C07K014/65
EP 854884 A1	July 29, 1998	E	000	C07K014/65
JP 11508608 W	July 27, 1999	N/A	034	C07K014/65
MX 9710291 A1	August 1, 1998	N/A	000	C07K014/65

INT-CL (IPC): A61K 38/00; A61K 38/30; A61K 45/00; A61P 5/50; C07K 14/65; G01N 33/15; G01N 33/74

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

[Generate Collection](#)

Term	Documents
IGF.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	3224
IGFS.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	233
RESPONSIVE.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	436182
RESPONSIVES.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	7
CONDITION.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	1389874
CONDITIONS.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	1498761
(1 AND (IGF ADJ RESPONSIVE ADJ CONDITION)).USPT,PGPB,JPAB,EPAB,DWPI,TDBD.	2

Display

10

Documents, starting with Document:

2

Display Format:

REV

Change Format

WEST**End of Result Set**

Generate Collection

L5: Entry 2 of 2

File: DWPI

May 11, 2000

DERWENT-ACC-NO: 1997-526402

DERWENT-WEEK: 200031

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Ligand inhibitor of insulin-like growth factor binding - used to increase level of free growth factor and treat growth factor-responsive conditions

DID:

WO 9739032 A1

ABTX:

A novel ligand inhibitor (A) that inhibits binding of insulin-like growth factor (IGF) to IGF binding protein (IGFBP) is used for: (a) increasing the level of free, biologically active IGF in a patient; or (b) treating an IGF-responsive condition. Also new are: (1) a method for screening for small molecule (A); and (2) ligand inhibitors (A') that inhibit binding of some protein (I) to IGFBP used in a method for increasing the level of free, active (I).

WEST[Generate Collection](#)**Search Results - Record(s) 1 through 1 of 1 returned.**☐ 1. Document ID: EP 1117424 A2, WO 200020023 A2, AU 9962778 A

L1: Entry 1 of 1

File: DWPI

Jul 25, 2001

DERWENT-ACC-NO: 2000-303638

DERWENT-WEEK: 200143

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Treating cancers of the breast, lung and prostate using null insulin-like growth factor

INVENTOR: MASCARENHAS, D

PRIORITY-DATA: 1999US-0399120 (September 20, 1999), 1998US-0102747 (October 2, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1117424 A2	July 25, 2001	E	000	A61K038/30
WO 200020023 A2	April 13, 2000	E	016	A61K038/30
AU 9962778 A	April 26, 2000	N/A	000	A61K038/30

INT-CL (IPC): A61K 31/505; A61K 38/30; A61K 38/30; A61P 35/00; A61K 38/30; A61K 31/505

Full	Title	CIT.1	REV.1	CLS.1	REF.1	DRAW.1
------	-------	-------	-------	-------	-------	--------

[Generate Collection](#)

Term	Documents
NULL.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	45859
NULLS.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	4042
INSULIN.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	27370
INSULINS.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	541
LIKE.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	2605290
LIKES.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	3106
(NULL ADJ (INSULIN ADJ LIKE)).USPT,PGPB,JPAB,EPAB,DWPI,TDBD.	1

[Display](#)[10](#)

Documents, starting with Document:

[1](#)

Display Format: REV Change Format

WEST**End of Result Set**

Generate Collection

L1: Entry 1 of 1

File: DWPI

Jul 25, 2001

DERWENT-ACC-NO: 2000-303638

DERWENT-WEEK: 200143

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Treating cancers of the breast, lung and prostate using null insulin-like growth factor

INVENTOR: MASCARENHAS, D

PRIORITY-DATA: 1999US-0399120 (September 20, 1999), 1998US-0102747 (October 2, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1117424 A2	July 25, 2001	E	000	A61K038/30
WO 200020023 A2	April 13, 2000	E	016	A61K038/30
AU 9962778 A	April 26, 2000	N/A	000	A61K038/30

INT-CL (IPC): A61K 31/505; A61K 38/30; A61K 38/30; A61P 35/00; A61K 38/30; A61K 31/505

ABSTRACTED-PUB-NO: WO 200020023A

BASIC-ABSTRACT:

NOVELTY - A method (I) for alleviating the symptoms of cancer (or slowing the progression of the cancer), comprising administering null insulin-like growth factor I (IGF-I) to a cancer patient, is new.

ACTIVITY - Cytostatic.

Y60L IGF-I and Y60L IGF-I/N109D, N172D IGFBP-3 (IGF binding protein-3) complex were tested for antitumor activity in nude mice. 36 mice which had been implanted with PC-3 (human prostate) tumor xenografts were obtained. Each mouse had received a subcutaneous xenograft of approximately 4-6 mm³ solid PC-3 tumor. Three different test compositions were used:

(1) 2 mg/kg/day Y60L IGF-I (null160 IGF-I) dissolved in 50 mM sodium acetate, pH 5.5, 108 mM sodium chloride (vehicle);

(2) 10 mg/kg/day Y60L IGF-I/N109D, N172D IGFBP-3 complex (null160 IGF-I complex) dissolved in the vehicle; and

(3) the vehicle alone (control).

The test compositions were administered near the xenograft site twice each weekday (Monday through Friday) and once per weekend day (Saturday and Sunday) by subcutaneous bolus injection. Test compositions were administered from day 15 after implantation (Day 15) until the animal was sacrificed. Animals were sacrificed at day 57 after implantation (Day 57) or earlier if tumor volume exceeded 2000 mm³. Tumor growth was measured three times per week using calipers. Statistical analysis was performed using a two-tailed t test. Any

animal that did not show evidence of tumor growth by Day 23 was eliminated from the study. 12 null160 IGF-I, 9 null160 IGF-I complex, and 11 control treated mice remained in the study after Day 23.

Results of this experiment are given in the specification. Survival of the control and null160 complex animals were very similar (average survival 30.6 days and 31.1 days (respectively), $p=0.795$). However, mice treated with null160 IGF-I had substantially greater survival, with an average survival of 35.25 days at the end of the study ($p=0.067$ compared with control). It was noted that the average survival of the null160 IGF-I treated mice was underestimated by this experiment, as 2 null160 IGF-I treated mice had tumors of less than 2000 mm³ at the end of the study. It was also found that median survival was substantially increased for mice receiving null160 IGF-I.

MECHANISM OF ACTION - The null IGF-1 has reduced receptor binding affinity.

USE - Method (I) is preferably used to treat breast, prostate, colon and/or lung cancer (claimed).

ADVANTAGE - The use of null IGF-I to treat cancer avoids the side effects associated with conventional chemotherapy such as alopecia, leukopenia and mucositis.

ABSTRACTED-PUB-NO: WO 200020023A
EQUIVALENT-ABSTRACTS:

CHOSEN-DRAWING: Dwg.0/2

WEST**End of Result Set**

Generate Collection

L3: Entry 1 of 1

File: DWPI

Jul 25, 2001

DERWENT-ACC-NO: 2000-303638

DERWENT-WEEK: 200143

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Treating cancers of the breast, lung and prostate using null insulin-like growth factor

INVENTOR: MASCARENHAS, D

PATENT-ASSIGNEE:

ASSIGNEE

CODE

CELTRIX PHARM INC

CELTN

PRIORITY-DATA: 1999US-0399120 (September 20, 1999), 1998US-0102747 (October 2, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1117424 A2	July 25, 2001	E	000	A61K038/30
<u>WO 200020023 A2</u>	April 13, 2000	E	016	A61K038/30
AU 9962778 A	April 26, 2000	N/A	000	A61K038/30

DESIGNATED-STATES: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE AU
CA JP AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
EP 1117424A2	September 29, 1999	1999EP-0950037	N/A
EP 1117424A2	September 29, 1999	1999WO-US22681	N/A
EP 1117424A2		WO 200020023	Based on
WO 200020023A2	September 29, 1999	1999WO-US22681	N/A
AU 9962778A	September 29, 1999	1999AU-0062778	N/A
AU 9962778A		WO 200020023	Based on

INT-CL (IPC): A61K 31/505; A61K 38/30; A61K 38/30; A61P 35/00; A61K 38/30; A61K 31/505

ABSTRACTED-PUB-NO: WO 200020023A

BASIC-ABSTRACT:

NOVELTY - A method (I) for alleviating the symptoms of cancer (or slowing the progression of the cancer), comprising administering null insulin-like growth factor I (IGF-I) to a cancer patient, is new.

ACTIVITY - Cytostatic.

Y60L IGF-I and Y60L IGF-I/N109D, N172D IGFBP-3 (IGF binding protein-3) complex

were tested for antitumor activity in nude mice. 36 mice which had been implanted with PC-3 (human prostate) tumor xenografts were obtained. Each mouse had received a subcutaneous xenograft of approximately 4-6 mm³ solid PC-3 tumor. Three different test compositions were used:

- (1) 2 mg/kg/day Y60L IGF-I (null160 IGF-I) dissolved in 50 mM sodium acetate, pH 5.5, 108 mM sodium chloride (vehicle);
- (2) 10 mg/kg/day Y60L IGF-I/N109D, N172D IGFBP-3 complex (null160 IGF-I complex) dissolved in the vehicle; and
- (3) the vehicle alone (control).

The test compositions were administered near the xenograft site twice each weekday (Monday through Friday) and once per weekend day (Saturday and Sunday) by subcutaneous bolus injection. Test compositions were administered from day 15 after implantation (Day 15) until the animal was sacrificed. Animals were sacrificed at day 57 after implantation (Day 57) or earlier if tumor volume exceeded 2000 mm³. Tumor growth was measured three times per week using calipers. Statistical analysis was performed using a two-tailed t test. Any animal that did not show evidence of tumor growth by Day 23 was eliminated from the study. 12 null160 IGF-I, 9 null160 IGF-I complex, and 11 control treated mice remained in the study after Day 23.

Results of this experiment are given in the specification. Survival of the control and null160 complex animals were very similar (average survival 30.6 days and 31.1 days (respectively), $p=0.795$). However, mice treated with null160 IGF-I had substantially greater survival, with an average survival of 35.25 days at the end of the study ($p=0.067$ compared with control). It was noted that the average survival of the null160 IGF-I treated mice was underestimated by this experiment, as 2 null160 IGF-I treated mice had tumors of less than 2000 mm³ at the end of the study. It was also found that median survival was substantially increased for mice receiving null160 IGF-I.

MECHANISM OF ACTION - The null IGF-1 has reduced receptor binding affinity.

USE - Method (I) is preferably used to treat breast, prostate, colon and/or lung cancer (claimed).

ADVANTAGE - The use of null IGF-I to treat cancer avoids the side effects associated with conventional chemotherapy such as alopecia, leukopenia and mucositis.

CHOSEN-DRAWING: Dwg.0/2

TITLE-TERMS: TREAT CANCER BREAST LUNG PROSTATE NULL INSULIN GROWTH FACTOR

DERWENT-CLASS: B03 B04

CPI-CODES: B04-B04D2; B04-C01; B04-F02; B04-H06; B04-N02; B07-D09; B07-D12; B11-C01; B12-M05; B14-H01; B14-L06; B14-N07A;

CHEMICAL-CODES:

Chemical Indexing M1 *01*

Fragmentation Code

M423 M431 M782 M905 N135 P633

Specific Compounds

A11A9K A11A9T A11A9M

Chemical Indexing M2 *02*

Fragmentation Code

F012 F014 F016 F542 J5 J521 J592 J9 L9 L910

M210 M213 M231 M240 M281 M320 M413 M431 M510 M521

M530 M540 M782 M904 M905 M910 P610

Specific Compounds
00051K 00051T 00051M
Registry Numbers
0051U

Chemical Indexing M2 *03*

Fragmentation Code
F011 F012 F522 H1 H181 H2 H201 H4 H492 H9
L9 L922 M210 M211 M273 M281 M320 M413 M431 M510
M521 M530 M540 M782 M904 M905 P610
Specific Compounds
03181K 03181T 03181M

Chemical Indexing M2 *04*

Fragmentation Code
F011 F012 F013 F522 H2 H212 J5 J521 K0 L4
L463 L9 L921 M210 M211 M212 M272 M273 M281 M320
M413 M431 M510 M521 M530 M540 M782 M904 M905 M910
P610
Specific Compounds
02023K 02023T 02023M
Registry Numbers
2023U

UNLINKED-DERWENT-REGISTRY-NUMBERS: 0051U; 2023U

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C2000-092169